Stocktoria
Curanex Pharmaceuticals Inc CURX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-08-26
Curanex Pharmaceuticals Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $3.0M | — |
| Operating income | -$4.2M | -$365,062 |
| Net income | -$4.2M | -$361,506 |
| EPS (diluted) | $-0.17 | $-0.03 |
| Operating cash flow | -$10.5M | -$555,575 |
| Cash & equivalents | $5.0M | — |
| Total assets | $11.6M | $517,935 |
| Total liabilities | $361,040 | $14,575 |
| Shareholders' equity | $11.2M | $503,360 |
Source: SEC EDGAR filings · CIK 0002025942 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.